Claritus Pharmaceuticals Inc. (CLAZF)

[Skydive21]

April 7 2022 -- Claritas has received approval from the OTC Markets to list its Common Shares for trading on the OTCQB
The OTCQB listing will elevate the Company’s profile and introduce the Company to a broader investor audience in the U.S.
Robert Farrell, the Company’s President and CEO, commented, "We are very pleased to report that we have met all requirements and have been accepted by OTC Markets to up-list to the OTCQB tier for trading. We undertook the stringent qualification process for the OTCQB listing because we believe that trading on the OTCQB tier will bring added value to our shareholders. The OTCQB listing will elevate our profile within the investment community and is consistent with our long-term strategy to introduce the Company to a broader investor audience in the U.S. This upgrade is a significant milestone and a step toward the NASDAQ listing that we anticipate will occur next year."

The OTCQB is recognized by the Securities and Exchange Commission (“SEC”) as an established public market providing data that investors need to analyze, value and trade securities. Being part of an established financial marketplace will assist in diversifying the Company’s shareholder base with increased liquidity and brand visibility while maintaining a high level of transparent trading, annual verification, continuous regulation and provide a strong baseline of transparency to inform and engage investors. The requirements and standards for OTCQB can be found at https://www.otcmarkets.com/corporate-services/get-started/otcqb.